Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Cost of Revenue (2016 - 2025)

United Therapeutics' Cost of Revenue history spans 17 years, with the latest figure at $103.4 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 36.23% year-over-year to $103.4 million; the TTM value through Dec 2025 reached $384.4 million, up 24.12%, while the annual FY2025 figure was $384.4 million, 24.12% up from the prior year.
  • Cost of Revenue for Q4 2025 was $103.4 million at United Therapeutics, up from $100.9 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $103.4 million in Q4 2025 and bottomed at $23.0 million in Q1 2021.
  • The 5-year median for Cost of Revenue is $67.1 million (2023), against an average of $61.3 million.
  • The largest annual shift saw Cost of Revenue dropped 20.16% in 2022 before it surged 115.82% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $34.6 million in 2021, then skyrocketed by 69.94% to $58.8 million in 2022, then grew by 20.75% to $71.0 million in 2023, then rose by 6.9% to $75.9 million in 2024, then soared by 36.23% to $103.4 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Cost of Revenue are $103.4 million (Q4 2025), $100.9 million (Q3 2025), and $87.6 million (Q2 2025).